cephalosporin c has been researched along with meropenem in 288 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.69) | 18.7374 |
| 1990's | 56 (19.44) | 18.2507 |
| 2000's | 65 (22.57) | 29.6817 |
| 2010's | 108 (37.50) | 24.3611 |
| 2020's | 57 (19.79) | 2.80 |
| Authors | Studies |
|---|---|
| Donnelly, JP | 1 |
| Harabe, E; Kanazawa, K; Kawai, Y; Nishino, T; Otsuki, M | 1 |
| Hopkins, JA; Lami, JL; Wilson, SE | 1 |
| Mitsuhashi, S; Sumita, Y | 1 |
| Beumer, H; Hoepelman, IM; Rozenberg-Arska, M; Verhoef, J; Visser, MR | 1 |
| Chanal, C; Labia, R; Morand, A; Sirot, D; Tiwari, K | 1 |
| Hikida, M; Kawashima, K; Mitsuhashi, S; Nishiki, K; Yamazaki, Y; Yoshida, M | 1 |
| Ehrett, S; Friedland, IR; Hickey, S; McCracken, GH; Olsen, K; Paris, M | 1 |
| Coulthard, M; Ehrett, S; Friedland, IR; Jafari, H; McCracken, GH; Olsen, K; Paris, M; Rinderknecht, S; Saxen, H | 1 |
| Byrne, S; Connor, P; David, TJ; Dodd, M; Doughty, I; Jenney, M; Maddison, J; Webb, AK | 1 |
| Edwards, JR; Nairn, K; Shepherd, GL | 1 |
| Schuler, D | 1 |
| Coronel, P; Fernández-Roblas, R; Gimeno, M; López, JC; Ramos, JM; Soriano, F | 1 |
| Cavalier, A; Elkhaïli, H; Jehl, F; Kaltenbach, G; Levêque, D; Monteil, H; Peter, JD; Salmon, J; Salmon, Y | 1 |
| Komoto, A; Nishino, T; Otsuki, M | 1 |
| Deguchi, K; Fukayama, S; Fukumoto, T; Ishihara, R; Koguchi, M; Nakane, Y; Oda, S; Suzuki, Y; Tanaka, S | 1 |
| Hoppe, JE; Rahimi-Galougahi, E; Seibert, G | 1 |
| Jiang, GZ; Kato, Y; Kido, N; Koide, N; Kusumi, A; Narita, K; Sugiyama, T; Takahashi, K; Yokochi, T | 1 |
| Adachi, Y; Fuse, A; Hashizume, T; Kato, E; Nagano, R; Nakagawa, S; Ohtake, N; Okamoto, O; Shibata, K | 1 |
| Mandell, GL; Townsend, GC | 1 |
| Blahová, J; Králiková, K; Krcméry, V; Kubonová, K | 1 |
| Nieto, E; Parra, A; Ponte, C; Soriano, F | 1 |
| Iaconis, JP; Nadler, HL; Pitkin, DH; Sheikh, W | 1 |
| Nadler, HL; Pitkin, DH; Sheikh, W | 1 |
| Hathorn, JW; Lyke, K | 1 |
| Elkhaïli, H; Jehl, F; Levêque, D; Linger, L; Monteil, H; Niedergang, S; Peter, JD; Pompei, D; Salmon, J; Salmon, Y; Thierry, RC | 1 |
| Hirata, Y; Igari, J; Imafuku, Y; Inoue, M; Ishigo, S; Kawaguchi, R; Kobayashi, I; Kumasaka, K; Matsuoka, K; Murakami, E; Nishino, T; Oguri, T; Ohtaki, Y; Okada, J; Okamoto, E; Saeki, H; Satou, S; Shibano, T; Takahashi, A; Tokuda, K; Uchida, K; Uehara, N; Watanabe, N; Yomoda, S; Yoshida, H | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 1 |
| Berman, SJ; Farkas, SA; Geckler, RW; Sieger, B | 1 |
| Jarque, I; Larrea, L; Sanz, MA | 1 |
| Battles, A; Liu, QF; Liu, W; Louie, A; Miller, DA; Miller, MH; Sucke, AC | 1 |
| Klastersky, J | 1 |
| Friedland, IR; Lutsar, I | 1 |
| Finch, RG; Gildon, KM; Pemberton, K | 1 |
| Aleksandrova, IA; Grudinina, SA; Rezvan, SP; Sidorenko, SV; Sterkhova, GV | 1 |
| Behre, G; Hiddemann, W; Link, H; Maschmeyer, G; Meyer, P; Paaz, U; Wilhelm, M | 1 |
| Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
| Benali, K; Bingen, E; Bonacorsi, S; Doit, C; Fitoussi, F; Geslin, P | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Marchisio, P; Principi, N | 1 |
| Barberán, J; Campos, A; García, MC; Khorrami, S | 1 |
| Au, C; Chan, CY; Cheng, AF; Cheung, SW; Ip, M | 1 |
| Sieger, B | 1 |
| Ispahani, P; Punt, J; Vloebeghs, M; Watson, AR; Weston, VC | 1 |
| Adriansson, M; Andreasson, B; Bäckström, B; Johansson, P; Karlsson, K; Lindblad, R; Rhedin, C; Rödjer, S; Turesson, I | 1 |
| Ho, SW; Hsueh, PR; Jan, IS; Luh, KT; Teng, LJ | 1 |
| Kinoshita, S; Kumagai, S | 1 |
| Berger, D; Heinemann, M; Möricke, A; Seidelmann, M; Trautmann, M; Zick, R | 1 |
| Chan, WC; Cheng, AF; Li, RC; Ling, JM; Schentag, JJ | 1 |
| Gildon, KM; Norrby, SR | 1 |
| Bradley, JS; Feris, JM; Khan, WN; McCracken, GH; Odio, CM; Puig, JR; Rodriguez, WJ | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Arita, K; Daido, K; Kohara, T; Nakamura, K; Ohashi, N; Takeshima, Y | 1 |
| Cho, JH; Jin, C; Jung, I; Kim, DH; Kim, M; Ku, HJ; Oh, CH; Yook, J | 1 |
| Cottagnoud, M; Cottagnoud, P; Gerber, CM; Neftel, KA; Täuber, MG | 1 |
| Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
| Deguchi, K; Endo, H; Ishihara, R; Matsumoto, Y; Nishinari, C; Suzuki, Y | 1 |
| Jacolot, A; Leotard, S; Louchahi, K; Mimoz, O; Nordmann, P; Padoin, C; Petitjean, O | 1 |
| Norrby, SR | 1 |
| Ferrant, A; Gérain, J; Humblet, Y; Longueville, J; Moreau, M; Straetmans, N; Symann, M; Vandercam, B; Wauters, G | 1 |
| Christenson, JC; Daly, JA; Korgenski, EK | 1 |
| Berman, S; DePauw, B; Feld, R; Ho, W; Keating, A | 1 |
| Jones, RN | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Inoue, M; Matsuda, K | 1 |
| Bode, U; Fleischhack, G; Hartmann, C; Hasan, C; Havers, W; Marklein, G; Simon, A; Wulff, B | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Clarke, AR; Spencer, J; Walsh, TR | 1 |
| Agaoglu, L; Agirbasli, H; Anak, S; Bilgen, H; Biner, B; Can, M; Devecioglu, O; Eryilmaz, E; Gedikoglu, G; Goksan, B; Karakas, Z; Unuvar, A; Yalman, N | 1 |
| Clair, A; Golledge, CL; Harvey, J; Inglis, TJ | 1 |
| Abe, T; Fukuoka, T; Inoue, H; Ohya, S | 1 |
| Ghaffar, F; Hardy, RD; Jafri, HS; McCoig, CC; McCracken, GH; Michelow, IC; Olsen, K; Patel, C; Rodriguez-Cerrato, V | 1 |
| Endo, H; Jinbo, K; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
| Anthony, L; Appelbaum, PC; Credito, K; Ednie, LM; Hoellman, DB; Jacobs, MR; Kelly, LM | 1 |
| Chen, M; Liu, J; Wang, C; Wang, H; Wang, P; Xie, X; Xu, Y; Yuan, Y; Zhang, X; Zhang, Y | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Kocabalkan, F; Mas, MR; Mas, NN; Sağlamkaya, U; Simşek, I; Yaşar, M | 1 |
| Malik, I | 1 |
| Araake, M; Gotoh, N; Hiraishi, T; Miyata, A; Nishino, T; Ogawa, H; Takata, T | 1 |
| Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A; Odenholt, I | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Furugo, I; Ishida, M; Takii, M; Ueda, M | 1 |
| Dawis, MA; France, KA; Isenberg, HD; Jenkins, SG | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Beketov, AS; Komarov, RM; Pisarev, VV; Sidorenko, SV | 1 |
| Jones, RN; Rhomberg, PR | 1 |
| Hashimoto, K; Ito, K; Ogata, H | 1 |
| Ceran, N; Erdem, I; Kucukercan, M | 1 |
| Akyüz, C; Büyükpamukçu, M; Ceyhan, M; Kanra, G; Kurne, O; Kutluk, T; Seçmeer, G | 1 |
| Anstey, NM; Cheng, AC; Currie, BJ; Fisher, DA; Jacups, SP; Stephens, DP | 1 |
| Burgess, DS; Hall, RG | 1 |
| Currie, BJ; Inglis, TJ; Norton, R; Rigby, P; Rodrigues, F | 1 |
| Ammosov, VG; Ignat'ev, VV; Vinokurov, MM | 1 |
| Bernabéu-Wittel, M; de Cueto, M; del Carmen Conejo, M; García, I; Jiménez-Mejías, ME; Martínez-Martínez, L; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C | 1 |
| Hasui, T; Ishiyama, S; Itoshima, T; Kajitani, N; Shiode, J; Takada, S; Yamamoto, K | 1 |
| Demiroz, AP; Ertem, G; Hatipoglu, CA; Irmak, H; Kinikli, S; Kocak, Z; Tufan, A | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Arisoy, AE; Arisoy, ES; Gundes, S; Karaali, E; Kolayli, F; Sanic, A; Turker, G; Vahaboglu, H | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Greenberg, A; Muallem-Zilcha, E; Raveh, D; Schlesinger, Y; Wiener-Well, Y; Yinnon, AM | 1 |
| Albertí, S; Alonso, D; Borrell, N; Doménech-Sánchez, A; Gomez, C; Padilla, E; Pérez, JL | 1 |
| Arakawa, S; Deguchi, T; Egashira, T; Fujime, M; Fujita, K; Fukuhara, Y; Furuya, N; Hirakata, Y; Hirose, T; Igari, J; Imafuku, Y; Ishibashi, K; Ishihara, S; Kamidono, S; Kitamura, M; Kobayashi, Y; Kohno, S; Kondo, A; Konishi, T; Kumamoto, Y; Kumon, H; Kunishima, Y; Matsuda, J; Matsuda, S; Matsukawa, M; Matsumoto, T; Monden, K; Murai, M; Muratani, T; Naito, S; Nakano, M; Oguri, T; Oka, T; Ooe, H; Sato, S; Shigeta, S; Suzutani, T; Tsukamoto, T; Uchida, H; Watanabe, K; Yamaguchi, K; Yamaguti, O; Yoshida, H | 1 |
| Li, C; Nicolau, DP; Nightingale, CH; Ong, CT; Tessier, PR | 1 |
| Agarwal, N; Agarwal, S; Arya, SC | 1 |
| Satti, F; Shames, R; Smith, MA; Vellozzi, EM | 1 |
| Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP | 1 |
| Bokaei, S; Etemadi, G; Feizabadi, MM; Rahmati, M; Shabanpoor, S; Yadegarinia, D | 1 |
| Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
| Sakata, H | 1 |
| Agarwal, N; Agarwal, S; Arya, SC; Solanki, BS | 1 |
| Chen, YS; Chiu, CJ; Chu, C; Lee, CH; Liu, JW; Su, LH | 1 |
| Billal, DS; Hotomi, M; Yamanaka, N | 1 |
| Afonso, MR; Albertoni, Ade C; Arkader, R; Cabral, EA; da Silva, DC; de Araujo, OR; Diegues, AR; Louzada, ME | 1 |
| Giamarellou, H | 1 |
| Charlier, C; Denooz, R | 1 |
| Cabellos, C; Domenech, A; Force, E; Gudiol, F; Ribes, S; Taberner, F; Tubau, F; Viladrich, PF | 1 |
| Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
| Dehority, W; Leake, JA | 1 |
| Eagye, KJ; Kuti, JL; Nicasio, AM; Nicolau, DP; Palter, M; Pepe, J; Shore, E | 1 |
| Stiefelhagen, P | 1 |
| Amicosante, G; Falcone, M; Mancini, C; Mezzatesta, ML; Perilli, M; Stefani, S; Venditti, M | 1 |
| Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P | 1 |
| Faccone, D; Galas, M; López, Y; Maggi, G; Marcano, D; Pasterán, F; Payares, D; Rapoport, M; Salgado, N; Sánchez, D; Spadola, E; Ugarte, C | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Appelbaum, PC; Ednie, LM; Lin, G; Pankuch, GA | 1 |
| Kuti, JL; Nicolau, DP | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Chumjan, W; Hajjar, E; Mahendran, KR; Schulte, A; Suginta, W; Weingart, H; Winterhalter, M | 1 |
| Bebrone, C; Docquier, JD; Favier, A; Ferrer, JL; Frère, JM; Galleni, M; Lassaux, P; Laurent, C; Loisel, E; Sohier, JS; Traoré, DA | 1 |
| Chang, FY; Chen, JH; Chen, TL; Fung, CP; Lin, JC; Siu, LK; Tsai, YK | 1 |
| Cabot, G; Macia, MD; Martínez-Martínez, L; Moya, B; Ocampo-Sosa, AA; Oliver, A; Peña, C; Rodríguez, C; Suárez, C; Tubau, F; Zamorano, L | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Altunsoy, A; Aypak, C; Azap, A; Balık, I; Ergönül, Ö | 1 |
| Cotton, F; De Backer, D; Jacobs, F; Macours, P; Seyler, L; Taccone, FS; Vincent, JL | 1 |
| Gonçalves-Pereira, J; Póvoa, P | 1 |
| Legros, B; Lorent, S; Naeije, G; Vincent, JL | 1 |
| Kronenberg, A; Mühlemann, K; Pannatier, A; Plüss-Suard, C; Ruffieux, C; Zanetti, G | 1 |
| Homann, C; Knudsen, JD; Moser, C; Novovic, S; Olsen, H; Semb, S | 1 |
| Komatsu, T; Takei, N | 1 |
| Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
| Arthur, M; Dubée, V; Dubost, L; Ethève-Quelquejeu, M; Gutmann, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Cullen, IM; Fennell, JP; Flynn, RJ; Grainger, R; Manecksha, RP; McDermott, T; McEvoy, E; Nason, GJ; Thornhill, JA | 1 |
| Aracil, B; Beceiro, A; Bou, G; Cercenado, E; Fernández, A; Kerff, F; Miro, E; Navarro, F; Oliver, A; Oteo, J; Pérez-Llarena, FJ; Zamorano, L | 1 |
| Arai, A; Fukuda, T; Kumekawa, H; Kurosu, T; Miura, O; Murakami, N; Murata, Y; Ohki, M; Sasaki, K; Yamamoto, M | 1 |
| Conklin, BC; Hutton, RA; Li, M; Skalweit, MJ; Taracila, MA | 1 |
| Hino, M; Kanamaru, A; Masaoka, T; Nakagawa, Y; Ohta, K; Ohyashiki, K; Suzuki, K; Tamura, K; Urabe, A | 1 |
| Kimura, S; Kitazawa, T; Koga, I; Makita, E; Matsunaga, N; Okugawa, S; Ota, Y; Seo, K; Yoshino, Y | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Acicbe, O; Coban, AY; Deveci, A; Durupinar, B; Tanyel, E; Yaman, G | 1 |
| Chen, Y; Jiang, H; Jin, L; Kong, X; Li, JQ; Liang, Z; Lu, J; Luo, C; Ye, F; Yu, K; Zhu, K | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H | 1 |
| Anwar, Z; Guy, JR; Lam, BL; Schatz, NJ; Sternau, LL; Winter, TW | 1 |
| Blanchard, JS; Chow, C; Xu, H | 1 |
| Goessens, WH; Melles, DC; Pitout, JD; Tommassen, J; van Boxtel, R; van der Bij, AK; van Ulsen, P | 1 |
| Araki, H; Suemaru, K; Takechi, K; Tanaka, A; Tanaka, M; Watanabe, S | 2 |
| Carroll, KC; Cosgrove, SE; Girdwood, SC; Gopaul, R; Harris, AD; Roberts, AA; Tamma, PD; Tekle, T | 1 |
| Goff, DA; Nicolau, DP | 1 |
| Browning, R; Darwiche, K; Freitag, L; Kioumis, I; Li, Q; Parrish, S; Petridis, D; Porpodis, K; Ritzoulis, C; Spyratos, D; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
| Chlebicki, MP; Kwa, AL; Lee, AL; Lee, W; Liew, LT; Lim, CL; Nah, SC; Wan, CN | 1 |
| Chen, Z; Kang, M; Li, D; Tao, C; Wang, T; Xie, Y | 1 |
| Baek, JY; Cho, SY; Chung, DR; Kang, CI; Kim, J; Kim, SH; Ko, KS; Peck, KR; Song, JH | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Hayakawa, K; Kirikae, T; Kubota, S; Kuroda, E; Kutsuna, S; Mezaki, K; Miyoshi-Akiyama, T; Nagamatsu, M; Ohmagari, N; Shimada, K; Sugiki, Y; Takeshita, N; Tojo, M | 1 |
| Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S | 1 |
| Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
| de la Torre, J; Del Arco, A; Faus, V; Fernández, F; García-Alegría, J; Montiel, N; Olalla, J; Prada, JL; Rivas, F; Tortajada, B | 1 |
| Gu, B; Mei, Y; Wen, Y; Xia, W; Zhang, X | 1 |
| Han, X; Hu, D; Li, Q; Qu, Y; Shen, L | 1 |
| Akiyama, N; Fukushima, T; Hatanaka, K; Hino, M; Kanamaru, A; Masaoka, T; Nakagawa, Y; Nakane, T; Ohyashiki, K; Takahashi, T; Tamaki, T; Tamura, K; Tanimoto, M; Tatsumi, Y; Urabe, A; Yoshida, I | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
| Cui, L; Su, J; Wang, J; Wen, X; Zuo, L | 1 |
| Aitha, M; Buynak, JD; Crowder, MW; Kang, JS; Liu, EM; Oelschlaeger, P; Yang, H; Zhang, AL | 1 |
| Chen, XJ; Crotty, DJ; Dubrovskaya, Y; Ladapo, JA; Louie, E; Papadopoulos, J; Scipione, MR | 1 |
| Asari, Y; Itoga, M; Kayaba, H; Morimoto, T; Nakamura, K; Okumura, K; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y | 1 |
| Chia, JH; Hsu, PC; Kuo, AJ; Lee, CH; Lee, MH; Su, TY; Ye, JJ | 1 |
| Blanchard, JS; Bonomo, RA; Hazra, S; Kurz, SG; Nguyen, L; Wolff, K | 1 |
| Crandon, JL; Ghazi, IM; Lesho, EP; McGann, P; Nicolau, DP | 1 |
| Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
| Ebi, N; Fujita, M; Ichinose, Y; Inoue, Y; Ishida, M; Kishimoto, J; Matsumoto, T; Takayama, K; Wataya, H | 1 |
| Brasca, M; Decimo, M; Silvetti, T | 1 |
| Bao, Y; Mo, Y; Qi, S; Qiu, B; Zeng, H; Zhang, N | 1 |
| Cohen, H; Peyko, V; Smalley, S | 1 |
| Abe, T; Furuuchi, T; Ida, T; Inamura, S; Morinaka, A; Sakakibara, S; Sakamaki, Y; Takata, T; Takayama, Y; Tsujii, N; Tsutsumi, Y; Yamada, K | 1 |
| Alkrouk, A; Buehrle, DJ; Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Calfee, DP; Eiras, DP; Furuya, EY; Gomez-Simmonds, A; Jenkins, SG; Kubin, CJ; Loo, A; Nelson, B; Satlin, MJ; Whittier, S | 1 |
| Chen, TL; Chuang, MF; Huang, WC; Kuo, SC; Lauderdale, TL; Lee, Y; Tseng, KC; Yang, YS | 1 |
| Fukuhara, N; Ishii, Y; Ito, A; Ito-Horiyama, T; Nakamura, R; Sato, T; Tateda, K; Tsuji, M; Yamaguchi, K; Yamano, Y | 1 |
| Addison, NO; Awuah-Mensah, G; Labi, AK; Labi, JE; Obeng-Nkrumah, N | 1 |
| Chen, J; Kong, C; Zhang, Y; Zhu, L; Zou, X | 1 |
| Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O | 1 |
| Bell, DT; Chauhan, V; Kaushik, A; Kumar, P; Lamichhane, G; Stevens, RL; Xia, F | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Cantón, R; Chang, KT; Gao, S; Ledesma, KR; Oliver, A; Phe, K; Sánchez-Díaz, AM; Tam, VH; Van Bambeke, F; Zamorano, L; Zhou, J | 1 |
| Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
| D'Arcy, S; Doumith, M; Findlay, J; Hopkins, KL; Howe, R; Mather, B; Meunier, D; Mustafa, N; Pike, R; Woodford, N; Wootton, M | 1 |
| Chesnel, L; Howland, K; Jacqueline, C | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Grupper, M; Nicolau, DP; Sutherland, C | 1 |
| Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND | 1 |
| Burgess, DR; Burgess, DS; Cotner, SE; Martin, CA; Rutter, WC; Wallace, KL | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL | 1 |
| Keller, PM; Müller, DM; Rominski, A; Sander, P; Schulthess, B | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Lasco, TM; Ledesma, KR; Skoglund, E; Tam, VH | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Feng, H; Fleming, J; Liu, W; Liu, X; Wang, DC; Wang, S | 1 |
| Almuzara, M; Chiem, K; Collins, C; Iriarte, A; Montaña, S; Mussi, MA; Ramirez, MS; Saigo, M; Tolmasky, M; Traglia, G; Vay, C | 1 |
| Hao, D; Hu, Z; Liu, X; Sun, T; Tian, H; Wang, T; Wang, X | 1 |
| Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Ejaz, A; Ejaz, H; Javed, H; Saleem, R; Younas, S; Zafar, A | 1 |
| Börjesson, S; Magnusson, U; Sokerya, S; Sothyra, T; Ström Hallenberg, G | 1 |
| Adam, HJ; Domalaon, R; Golden, AR; Idowu, T; Karlowsky, JA; Lagacé-Wiens, PRS; Lawrence, CK; Lynch Iii, JP; Noreddin, A; Schweizer, F; Walkty, AJ; Wiebe, K; Zelenitsky, S; Zhanel, GG; Zhanel, MA | 1 |
| Funaishi, K; Hattori, N; Katsutani, S; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Bernard, S; Lee, K; Pakyz, A; Stevens, M; Vaughan, D | 1 |
| Hoban, DJ; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Papp-Wallace, KM | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Kalil, AC; Zavascki, AP | 1 |
| Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG | 1 |
| Lai, CC; Tang, HJ | 1 |
| Baillon-Plot, N; Bassetti, M; Charbonneau, C; Di Virgilio, R; Eckmann, C; Kongnakorn, T; Tichy, E | 1 |
| Anugulruengkitt, S; Chautrakarn, S; Hiransuthikul, N; Puthanakit, T; Rattananupong, T | 1 |
| Aitken, SL; Gerges, B; Prince, RA; Raad, I; Rolston, KVI; Shelburne, S | 1 |
| Millar, BC; Moore, JE; Moore, RE | 1 |
| Franz, KJ; Jackson, AC; Puccio, EA; Zaengle-Barone, JM | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Biswas, B; Bivens, BN; Brown, DE; Brownstein, MJ; Burch, AK; Daniels, R; Fackler, J; Gainey, AB; Horne, B; Malagon, F | 1 |
| Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
| Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
| Ariyasu, M; Clevenbergh, P; Echols, R; Kaye, KS; Kollef, M; Matsunaga, Y; Menon, A; Nagata, TD; Pogue, JM; Shorr, AF; Timsit, JF; Wunderink, RG; Zeitlinger, M | 1 |
| Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
| Ben-Ami, R; Bitterman, R; Cheng, MP; Chowers, M; Geffen, Y; Huberman Samuel, M; Koppel, F; Lee, TC; Leibovici, L; Mussini, C; Nesher, L; Paul, M; Rahav, G; Turjeman, A; Yahav, D | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Chatfield, MD; Harris, PNA; Littleford, R; Paterson, DL; Stewart, AG | 1 |
| Clabots, C; Johnson, JR; Johnston, BD; Porter, SB; Thuras, P | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Blumenthal, KG; Fu, X; Mancini, CM; Naureckas Li, C; Zhang, Y | 1 |
| Barrio-Tofiño, ED; Cortes-Lara, S; López-Causapé, C; Oliver, A | 1 |
| Pregnolato, M; Taccani, M; Terreni, M | 1 |
| Almeida, LGP; Arias, CA; Cayô, R; Dinh, AQ; Gales, AC; Hanson, B; Miller, WR; Nodari, CS; Santos, FF; Streling, AP; Vasconcelos, ATR | 1 |
| Belcher, R; Zobell, JT | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wolf, DJ; Wunderink, RG; Yu, B | 1 |
| Barrera Pulido, L; Borreguero Borreguero, I; Bustos de Godoy, N; Camean-Fernández, M; Gutiérrez-Gutiérrez, B; León, MJ; López-Cerero, L; López-Cortés, LE; Marín-Candón, A; Merino, V; Pascual, A; Retamar, P; Rodriguez-Baño, J; Rosso-Fernández, CM; Salamanca, E | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Attou, R; Barreto Gutierrez, L; Boer, W; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Moorthamers, S; Preseau, T; Redant, S | 1 |
| Bruno, CJ; Butterton, JR; Gates, D; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Motyl, M; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
| Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Baba, T; Echols, R; Paul, M; Portsmouth, S; Shields, RK; Timsit, JF; Yamano, Y | 1 |
| Bush, K; Carpenter, J; Chu, TY; Divoky, C; Lee-Hsiao, C; Neidig, N; Sultana, R; Threatt, H; Zhang, Q | 1 |
| Cremanns, M; Gatermann, SG; Lange, F; Pfennigwerth, N | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Batchelder, HR; Lamichhane, G; Nuermberger, EL; Panthi, CM; Rimal, B; Story-Roller, E; Tabor, C; Townsend, CA | 1 |
| Alt, V; Bärtl, S; Hitzenbichler, F; Lang, S; Rupp, M; Walter, N | 1 |
| Amadesi, S; Ambretti, S; Gaibani, P; Lazzarotto, T | 1 |
| Bassetti, M; Bruno, CJ; Castanheira, M; Huntington, JA; Jensen, EH; Johnson, MG; Motyl, M; Paterson, DL; Wolf, DJ; Yu, B | 1 |
| Wang, Y; Zhang, W | 1 |
| Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Findlay, J; Nordmann, P; Poirel, L; Rens, C | 1 |
| Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
| Azanza Perea, JR; Sádaba Díaz de Rada, B | 1 |
| Bandić-Pavlović, D; Barišić, I; Beader, N; Bedenić, B; Frančula-Zaninović, S; Krilanović, M; Pešorda, L; Schoenthaler, S; Veir, Z | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Bruno, CJ; Huntington, JA; Jensen, EH; Kollef, MH; Martin-Loeches, I; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH | 1 |
| Hsueh, PR; Lee, YL | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Berry, ED; Broadway, PR; Burdick Sanchez, NC; Carroll, JA; Fernando, SC; Hales, KE; Legako, JF; Long, NS; Wells, JE; Woerner, DR | 1 |
| Badawy, MSEM; Elkhatib, WF; Shebl, RI | 1 |
17 review(s) available for cephalosporin c and meropenem
| Article | Year |
|---|---|
Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Fever; Humans; Imipenem; Meropenem; Neutropenia; Thienamycins | 1997 |
[Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Imipenem; Meropenem; Neutropenia; Sepsis; Thienamycins | 1997 |
New antibiotics.
Topics: Anti-Infective Agents; Cefepime; Cephalosporins; Child; Fluoroquinolones; Humans; Meningitis, Bacterial; Meropenem; Naphthyridines; Thienamycins | 1998 |
Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Clindamycin; Diarrhea; Drug Eruptions; Humans; Imipenem; Meningitis; Meropenem; Nausea; Seizures; Thienamycins; Thrombocytosis | 1999 |
Carbapenems in serious infections: a risk-benefit assessment.
Topics: Adult; Cephalosporins; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Tolerance; Humans; Imipenem; Meningitis, Bacterial; Meropenem; Risk Assessment; Seizures; Thienamycins | 2000 |
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
beta-Lactams without a suicide inhibitor.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillins; Thienamycins | 2008 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Cefpirome; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Infections; Meropenem; Piperacillin; Thienamycins | 2011 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Molecular Structure; Randomized Controlled Trials as Topic; Siderophores | 2019 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Tazobactam | 2019 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines | 2021 |
Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.
Topics: Adult; Albumins; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood Proteins; Catechols; Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Humans; Iron; Meropenem | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
40 trial(s) available for cephalosporin c and meropenem
| Article | Year |
|---|---|
Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Topics: Adult; Aged; Bacterial Infections; Carbapenems; Cefmetazole; Cefoperazone; Cefotetan; Cefoxitin; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Escherichia coli Infections; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Remission Induction; Skin Diseases, Infectious; Staphylococcal Infections; Streptococcal Infections; Thienamycins | 1991 |
Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ceftazidime; Cephalosporins; Female; Fever; Humans; Leukemia; Leukocyte Count; Male; Meropenem; Middle Aged; Neutropenia; Prospective Studies; Thienamycins; Treatment Failure | 1995 |
Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
Topics: Adolescent; Adult; Carbapenems; Ceftazidime; Cephalosporins; Child, Preschool; Cystic Fibrosis; Drug Tolerance; Humans; Liver; Meropenem; Microbial Sensitivity Tests; Nausea; Pseudomonas Infections; Spirometry; Sputum; Thienamycins; Transaminases; Treatment Outcome; Vomiting | 1995 |
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cefotaxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Drug Tolerance; Humans; Infant; Meropenem; Metronidazole; Thienamycins | 1995 |
Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Prospective Studies; Respiratory Tract Infections; Thienamycins; Time Factors; Tobramycin | 1997 |
Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.
Topics: Adolescent; Adult; Age Factors; Aged; Ceftazidime; Cephalosporins; Community-Acquired Infections; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Risk Factors; Sex Factors; Thienamycins; Treatment Outcome | 1998 |
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Meropenem; Middle Aged; Neutropenia; Thienamycins | 1998 |
Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group.
Topics: Adolescent; Bacterial Infections; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Monitoring; Hospitalization; Humans; Infant; Infant, Newborn; Liver; Meropenem; Respiratory Tract Infections; Sepsis; Skin Diseases, Infectious; Thienamycins; Treatment Outcome; Urinary Tract Infections | 1998 |
Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftazidime; Cephalosporins; Female; Fever; Humans; Male; Meropenem; Middle Aged; Neutropenia; Opportunistic Infections; Thienamycins; Treatment Outcome | 1998 |
Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group.
Topics: Cefotaxime; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Meningitis, Bacterial; Meropenem; Prospective Studies; Single-Blind Method; Thienamycins; Treatment Outcome | 1999 |
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Tolerance; Female; Fever; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Thienamycins | 2000 |
Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftazidime; Cephalosporins; Double-Blind Method; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Prospective Studies; Thienamycins | 2000 |
Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
Topics: Bacterial Infections; Ceftazidime; Cephalosporins; Child; Child, Preschool; Escherichia coli; Female; Fever; Humans; Infant; Infant, Newborn; Klebsiella pneumoniae; Male; Meropenem; Neoplasms; Neutropenia; Prospective Studies; Relapsing Fever; Thienamycins; Time Factors; Treatment Outcome | 2001 |
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Topics: Adolescent; Adult; Amikacin; Cefepime; Cephalosporins; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fever; Humans; Infant; Male; Meropenem; Neoplasms; Netilmicin; Neutropenia; Prospective Studies; Thienamycins; Turkey | 2001 |
[Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Clinical Trials as Topic; Costs and Cost Analysis; Drug Combinations; Humans; Imipenem; Meropenem; Models, Economic; Sulbactam; Thienamycins | 2003 |
Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Child; Child, Preschool; Empiricism; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Meropenem; Neoplasms; Neutropenia; Therapeutic Equivalency; Thienamycins; Treatment Outcome | 2004 |
Outcomes of patients with melioidosis treated with meropenem.
Topics: Adolescent; Adult; Aged; Ceftazidime; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Melioidosis; Meropenem; Middle Aged; Prospective Studies; Sepsis; Thienamycins; Treatment Outcome | 2004 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Female; Fever; Hematologic Diseases; Humans; Male; Meropenem; Neutropenia; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2013 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; Cephalosporins; Ciprofloxacin; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Topics: Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intraabdominal Infections; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome | 2014 |
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cefozopran; Cephalosporins; Chemotherapy-Induced Febrile Neutropenia; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins; Young Adult | 2015 |
The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Cefepime; Cephalosporins; Febrile Neutropenia; Female; Humans; Lung Neoplasms; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 2016 |
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Tazobactam; Treatment Outcome | 2019 |
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Male; Meropenem; Pneumonia, Bacterial | 2021 |
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
Topics: Anti-Bacterial Agents; beta-Lactamases; Canada; Cephalosporins; Enterobacteriaceae; Humans; Israel; Italy; Meropenem; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Sepsis | 2021 |
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferior
Topics: Adult; Anti-Bacterial Agents; Australia; beta-Lactamases; Cephalosporins; Clostridioides difficile; Escherichia coli; Humans; Italy; Lebanon; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Saudi Arabia; Sepsis; Singapore; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Equivalence Trials as Topic; Female; Healthcare-Associated Pneumonia; Humans; Logistic Models; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tazobactam | 2021 |
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant
Topics: Bacteremia; Cephalosporins; Clinical Trials, Phase III as Topic; Enterobacteriaceae; Humans; Meropenem; Multicenter Studies as Topic; Penicillins; Pragmatic Clinical Trials as Topic; Randomized Controlled Trials as Topic | 2021 |
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Tazobactam; Ventilators, Mechanical | 2022 |
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Tazobactam; Ventilators, Mechanical | 2022 |
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; China; Double-Blind Method; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Tazobactam | 2022 |
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Monobactams; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Vasoconstrictor Agents; Ventilators, Mechanical | 2022 |
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
Antibimicrobial Susceptibility of Trimethoprim-Sulfamethoxazole and 3rd-Generation Cephalosporin-Resistant
Topics: Animals; Anti-Bacterial Agents; Cattle; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Male; Meropenem; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |
231 other study(ies) available for cephalosporin c and meropenem
| Article | Year |
|---|---|
Describing and comparing in-vitro antimicrobial activity by the box-plot technique.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Cephalosporins; Data Display; Meropenem; Methods; Microbial Sensitivity Tests; Thienamycins | 1992 |
In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
Topics: Animals; Bacterial Infections; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Male; Meropenem; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Thienamycins | 1992 |
In vitro synergistic activity between meropenem and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Cefazolin; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Imipenem; Meropenem; Methicillin Resistance; Staphylococcus aureus; Thienamycins | 1991 |
Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins; Ticarcillin | 1989 |
Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins.
Topics: Acylation; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Kinetics; Meropenem; Thienamycins | 1989 |
Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
Topics: Animals; Ceftazidime; Cephalosporins; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1995 |
Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cefpirome; Ceftriaxone; Cephalosporins; Disease Models, Animal; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Male; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Quinolones; Rabbits; Rifampin; Thienamycins; Vancomycin | 1993 |
Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis.
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Cefpirome; Cephalosporins; Chloramphenicol; Endotoxins; Escherichia coli Infections; Gentamicins; Inflammation; Male; Meningitis, Bacterial; Meropenem; Rabbits; Thienamycins | 1993 |
Efficacy of meropenem in experimental meningitis.
Topics: Ampicillin; Animals; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Evaluation; Drug Resistance, Microbial; Escherichia coli Infections; Gentamicins; Guinea Pigs; Haemophilus Infections; Haemophilus influenzae; Listeriosis; Meningitis, Bacterial; Meropenem; Neisseria meningitidis; Penicillin G; Pneumococcal Infections; Thienamycins | 1995 |
In-vitro activity of cefditoren against clinical isolates of penicillin-susceptible and resistant strains of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cephalosporins; Haemophilus influenzae; Meropenem; Microbial Sensitivity Tests; Neisseria meningitidis; Penicillin Resistance; Serum Bactericidal Test; Streptococcus pneumoniae; Thienamycins | 1996 |
[Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents].
Topics: Adult; Animals; Antibiotics, Antitubercular; Antifungal Agents; Catheterization, Peripheral; Cefepime; Cefpirome; Ceftriaxone; Cephalosporins; Disease Models, Animal; Female; Humans; Injections, Intravenous; Meropenem; Swine; Thienamycins | 1996 |
[In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Lactams; Male; Meropenem; Mice; Thienamycins | 1996 |
[Antimicrobial activities of meropenem against clinically isolated strains. The result against strains isolated from blood and cerebrospinal fluid].
Topics: Ampicillin; Blood; Cefotaxime; Cephalosporins; Cerebrospinal Fluid; Escherichia coli; Humans; Imipenem; Listeria monocytogenes; Meningitis, Bacterial; Meropenem; Penicillins; Sepsis; Streptococcus agalactiae; Streptococcus pneumoniae; Thienamycins | 1996 |
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Topics: Anti-Infective Agents; Bordetella; Bordetella Infections; Bordetella pertussis; Cefpirome; Cephalosporins; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins; Whooping Cough | 1996 |
Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide.
Topics: Carbapenems; Ceftazidime; Cephalosporins; Endotoxins; Imipenem; Lipopolysaccharides; Lymphotoxin-alpha; Meropenem; Nitric Oxide; Pseudomonas aeruginosa; Thienamycins; Tumor Necrosis Factor-alpha | 1996 |
In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Topics: Animals; Carbapenems; Ceftazidime; Cephalosporins; Culture Media; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Imipenem; In Vitro Techniques; Male; Meropenem; Mice; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1997 |
The new antibiotics, 1997.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Erythromycin; Fluoroquinolones; Humans; Macrolides; Meropenem; Penicillins; Piperacillin; Quinolones; Thienamycins | 1997 |
Hydrolysis of imipenem, meropenem, ceftazidime, and cefepime by multiresistant nosocomial strains of Sphingobacterium multivorum.
Topics: Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Drug Resistance, Microbial; Drug Resistance, Multiple; Flavobacterium; Gram-Negative Bacterial Infections; Humans; Hydrolysis; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1997 |
Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.
Topics: Amoxicillin; Animals; Cefotaxime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Guinea Pigs; Lung; Meropenem; Penicillin Resistance; Penicillins; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Thienamycins | 1996 |
Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Gentamicins; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 1997 |
Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Bacteria, Anaerobic; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Meropenem; Microbial Sensitivity Tests; Penicillins; Thienamycins | 1997 |
[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Perfusion; Serum Bactericidal Test; Swine; Thienamycins | 1997 |
[Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
Topics: 4-Quinolones; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Pseudomonas aeruginosa; Serratia marcescens; Thienamycins | 1997 |
Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 1997 |
[Monotherapy with meropenem in febrile granulocytopenic patients].
Topics: Agranulocytosis; Ceftazidime; Cephalosporins; Fever; Humans; Meropenem; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Thienamycins | 1997 |
Predictive value of several signs of infection as surrogate markers for mortality in a neutropenic guinea pig model of Pseudomonas aeruginosa sepsis.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Ceftazidime; Cephalosporins; Diarrhea; Disease Models, Animal; Female; Guinea Pigs; Imipenem; Meropenem; Movement Disorders; Neutropenia; Predictive Value of Tests; Pseudomonas Infections; Regression Analysis; Respiration; Thienamycins; Time Factors; Tobramycin; Weight Loss | 1997 |
[Comparative activity of meropenem and other antibiotics against the pathogens of nosocomial infections].
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Therapy, Combination; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins; Tobramycin | 1998 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meni
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cephalosporins; Child; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins; Vancomycin | 1998 |
Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Gentamicins; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Thienamycins; Time Factors | 1998 |
[Meningitis caused by Pseudomonas aeruginosa. Treatment with meropenem].
Topics: Aged; Blood-Brain Barrier; Cefepime; Cefotaxime; Cephalosporins; Cerebrospinal Fluid; Cerebrospinal Fluid Shunts; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Hydrocephalus; Male; Meningitis, Bacterial; Meropenem; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
A rapid high-performance liquid chromatographic assay for cefepime, cefpirome and meropenem.
Topics: Cefepime; Cefpirome; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Meropenem; Thienamycins | 1998 |
Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Critical Illness; Cross Infection; Drug Therapy, Combination; Humans; Meropenem; Pneumonia, Bacterial; Severity of Illness Index; Thienamycins; Tobramycin; Treatment Outcome | 1998 |
Listeria monocytogenes meningitis in a penicillin-allergic paediatric renal transplant patient.
Topics: Amoxicillin-Potassium Clavulanate Combination; Cefotaxime; Cephalosporins; Cerebrospinal Fluid; Child; Drug Hypersensitivity; Female; Humans; Immunocompromised Host; Kidney Transplantation; Listeria monocytogenes; Meningitis, Listeria; Meropenem; Thienamycins | 1998 |
Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics.
Topics: Anti-Infective Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Ciprofloxacin; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Ofloxacin; Thienamycins | 1998 |
[Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Imipenem; Meropenem; Monobactams; Norfloxacin; Tetracycline; Thienamycins | 1998 |
Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
Topics: Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Endotoxins; Humans; Imipenem; Lipopolysaccharides; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1998 |
Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefamandole; Cefepime; Cefoperazone; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Microbial; Enterobacter cloacae; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 1999 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
[Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; beta-Lactam Resistance; Carbapenems; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Ofloxacin; Pseudomonas aeruginosa; Thienamycins | 1999 |
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
Topics: Animals; Carbapenems; Cefazolin; Cephalosporins; GABA Agonists; Imipenem; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Muscimol; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Seizures; Synaptic Membranes; Thienamycins | 1999 |
Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.
Topics: Animals; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Thienamycins; Vancomycin | 1999 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
[Antimicrobial activities of meropenem against clinically isolated strains in 1997].
Topics: Bacteria; Carbapenems; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Thienamycins; Time Factors | 1999 |
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Half-Life; Imipenem; Kidney Diseases; Male; Meropenem; Penicillinase; Pneumonia, Bacterial; Protein Binding; Rats; Rats, Wistar; Thienamycins; Uranyl Nitrate | 2000 |
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefamandole; Cephalosporins; Data Collection; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
[Evaluation of antibiotics by the method of initial bactericidal activity].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Diffusion; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pyrrolidines; Thienamycins | 2001 |
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase.
Topics: beta-Lactamases; Catalysis; Cefaclor; Cephalosporins; Dose-Response Relationship, Drug; Hydrolysis; Indicators and Reagents; Kinetics; Meropenem; Models, Chemical; Spectrometry, Fluorescence; Stenotrophomonas maltophilia; Temperature; Thienamycins; Time Factors; Tryptophan; Ultraviolet Rays | 2001 |
Case report: recovery from persistent septicemic melioidosis.
Topics: Adult; Bacteremia; Burkholderia pseudomallei; Ceftazidime; Cephalosporins; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Melioidosis; Meropenem; Spleen; Thienamycins; Western Australia | 2001 |
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
Topics: Ampicillin; Animals; beta-Alanine; Cefozopran; Ceftriaxone; Cephalosporins; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Resistance; Imipenem; Male; Meropenem; Mice; Mice, Inbred Strains; Penicillin Resistance; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Thienamycins; Vancomycin | 2001 |
Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Ceftriaxone; Cephalosporins; Escherichia coli; Fluoroquinolones; Male; Meningitis, Escherichia coli; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Thienamycins | 2001 |
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Topics: Bacteria; Carbapenems; Cefepime; Cefozopran; Cephalosporins; Imipenem; Meropenem; Thienamycins | 2001 |
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Topics: Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cephalosporins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2002 |
In vitro activity of meropenem and four other antibiotics against 554 clinical strains obtained from Beijing in 1999.
Topics: Anti-Bacterial Agents; Cefepime; Cefoperazone; Ceftazidime; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; Meropenem; Thienamycins | 2000 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
Penetration of meropenem and cefepim into pancreatic tissue during the course of experimental acute pancreatitis.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ceruletide; Chromatography, High Pressure Liquid; Glycodeoxycholic Acid; Male; Meropenem; Pancreas; Pancreatitis, Acute Necrotizing; Rats; Rats, Sprague-Dawley; Thienamycins | 2002 |
Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
Topics: Adult; Antineoplastic Agents; Ceftazidime; Cephalosporins; Female; Fever; Humans; Male; Meropenem; Neoplasms; Neutropenia; Prospective Studies; Thienamycins | 2002 |
[Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Imipenem; Meropenem; Mutation; Pseudomonas aeruginosa; Thienamycins | 2002 |
Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ceftazidime; Cephalosporins; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Etoposide; Fluorouracil; Meropenem; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Thienamycins; Tobramycin | 2002 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
[Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999].
Topics: Adult; Aged; Ampicillin; Anti-Infective Agents; beta-Lactamases; Cefaclor; Cephalosporins; Child, Preschool; Female; Haemophilus influenzae; Humans; Imipenem; Infant; Infant, Newborn; Levofloxacin; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Respiratory System; Seasons; Sulbactam; Thienamycins | 2002 |
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Gentamicins; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Thienamycins | 2003 |
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
Topics: Anti-Bacterial Agents; Aztreonam; Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Female; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; North America; Sensitivity and Specificity; Thienamycins; Tobramycin | 2003 |
[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
Topics: Carbapenems; Cefoxitin; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Thienamycins; Tuberculosis, Pulmonary | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods.
Topics: Acanthamoeba; Animals; Burkholderia pseudomallei; Ceftazidime; Cephalosporins; Disease Outbreaks; Humans; Indicator Dilution Techniques; Indicators and Reagents; Melioidosis; Meropenem; Microbial Sensitivity Tests; Reproducibility of Results; Thienamycins; Treatment Outcome; Western Australia | 2004 |
[Optimization of strategy of surgical treatment for acute destructive pancreatitis].
Topics: Acute Disease; Anti-Bacterial Agents; Cephalosporins; Fluoroquinolones; Gastrointestinal Agents; Humans; Meropenem; Octreotide; Pancreatectomy; Pancreatitis; Postoperative Complications; Preoperative Care; Prognosis; Risk Factors; Thienamycins; Time Factors; Ultrasonography | 2004 |
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Guinea Pigs; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Thienamycins; Treatment Outcome | 2005 |
[Hepatic portal venous gas--a report of two cases successfully treated with conservative management].
Topics: Aged; Cefozopran; Cephalosporins; Clindamycin; Colitis; Colonic Diseases; Drug Therapy, Combination; Embolism, Air; Female; Gabexate; Gastrointestinal Hemorrhage; Humans; Ileitis; Meropenem; Portal Vein; Thienamycins; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2004 |
Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Candidiasis, Oral; Cefepime; Cephalosporins; Chlorhexidine; Drug Eruptions; Escherichia coli; Escherichia coli Infections; Exanthema; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Meropenem; Neutropenia; Nystatin; Platelet Transfusion; Prednisolone; Recombinant Proteins; Thienamycins; Thrombocytopenia; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
An outbreak of SHV-5 producing Klebsiella pneumoniae in a neonatal intensive care unit; meropenem failed to avoid fecal colonization.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cohort Studies; Cross Infection; Disease Outbreaks; DNA Fingerprinting; DNA, Bacterial; Feces; Female; Genes, Bacterial; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Isoelectric Focusing; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Molecular Epidemiology; Polymerase Chain Reaction; Random Amplified Polymorphic DNA Technique; Sequence Analysis, DNA; Thienamycins | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Utilization Review; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Colony Count, Microbial; Imipenem; In Vitro Techniques; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Plasmids; Pneumonia, Bacterial; Porins; Rats; Rats, Wistar; Thienamycins; Treatment Outcome | 2006 |
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Topics: Aminoglycosides; Ampicillin; Anti-Infective Agents; Aztreonam; Cefixime; Cefozopran; Cefpirome; Cefpodoxime; Ceftizoxime; Cephalosporins; Dibekacin; Drug Resistance, Bacterial; Enterococcus faecalis; Escherichia coli; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Proteus mirabilis; Pseudomonas aeruginosa; Quinolones; Serratia marcescens; Staphylococcus aureus; Thienamycins; Urinary Tract Infections; Vancomycin | 2006 |
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Imipenem; Membrane Transport Proteins; Meropenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms; Thienamycins; Thigh; Treatment Outcome | 2007 |
Evaluating broad-spectrum antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Ertapenem; Eye; Meropenem; Microbial Sensitivity Tests; Propionibacterium acnes; Rabbits; Thienamycins | 2006 |
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Hungary; Imipenem; Infusions, Intravenous; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2006 |
Antibiotic-resistance patterns and frequency of extended-spectrum beta-lactamase-producing isolates of Klebsiella pneumoniae in Tehran.
Topics: Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Female; Gentamicins; Humans; Imipenem; Iran; Klebsiella pneumoniae; Male; Meropenem; Thienamycins | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
[Relationship between protein binding and antimicrobial activities of antibiotics against Streptococcus pneumoniae and Haemophilus influenzae].
Topics: Administration, Oral; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Child; Haemophilus influenzae; Humans; Injections, Intravenous; Meropenem; Microbial Sensitivity Tests; Protein Binding; Streptococcus pneumoniae; Thienamycins | 2006 |
Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Hospitals, Urban; Humans; India; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2007 |
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Cephalosporins; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Electroporation; Ertapenem; Female; Genotype; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cephalosporins; Haemophilus influenzae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2007 |
Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Time Factors | 2007 |
Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cefuroxime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.
Topics: Animals; Cephalosporin Resistance; Cephalosporins; Disease Models, Animal; Guinea Pigs; Meningitis, Bacterial; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Rabbits; Streptococcus pneumoniae; Thienamycins | 2008 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
Fever, hip pain, and headache in a 12-year-old girl.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Diagnosis, Differential; Drug Therapy, Combination; Female; Fever; Fusobacterium Infections; Fusobacterium necrophorum; Headache; Hip; Humans; Magnetic Resonance Imaging; Meropenem; Thienamycins; Tomography, X-Ray Computed; Vancomycin | 2008 |
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Critical Pathways; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Observation; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Outcome; Vancomycin; Young Adult | 2010 |
[Backache with fever and shivering. Dangerous epidural abscess].
Topics: Anti-Bacterial Agents; Back Pain; Cefepime; Cephalosporins; Diagnosis, Differential; Drainage; Epidural Abscess; Fever; Humans; Male; Meropenem; Middle Aged; Myelography; Paresis; Prognosis; Radiography, Abdominal; Shivering; Staphylococcal Infections; Staphylococcus aureus; Thienamycins; Time Factors; Tomography, X-Ray Computed | 2009 |
Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamase-producing Proteus mirabilis: first report from Italy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Humans; Integrons; Italy; Male; Meropenem; Plasmids; Proteus Infections; Proteus mirabilis; Surgical Wound Infection; Thienamycins; Treatment Failure; Treatment Outcome | 2010 |
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Topics: Adult; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Fever; Hospital Mortality; Humans; Imipenem; Male; Meropenem; Middle Aged; Neutropenia; Retreatment; Seizures; Thienamycins; Time Factors | 2009 |
First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Child; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Quinolones; Thienamycins; Urine; Venezuela | 2008 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Synergism; Gentamicins; Lipoglycopeptides; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Rifampin; Thienamycins; Time Factors | 2010 |
Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Creatinine; Critical Pathways; Drug Administration Schedule; Humans; Meropenem; Pneumonia, Ventilator-Associated; Quality Assurance, Health Care; Renal Insufficiency; Thienamycins | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Molecular analysis of antimicrobial agent translocation through the membrane porin BpsOmp38 from an ultraresistant Burkholderia pseudomallei strain.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Outer Membrane Proteins; beta-Lactams; Biological Transport; Burkholderia pseudomallei; Cefepime; Ceftazidime; Cephalosporins; Ertapenem; Humans; Imipenem; Kinetics; Lipid Bilayers; Melioidosis; Meropenem; Models, Molecular; Molecular Sequence Data; Norfloxacin; Penicillin G; Phospholipids; Porins; Protein Conformation; Sequence Homology, Amino Acid; Thienamycins | 2011 |
Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cephalothin; Crystallography, X-Ray; Escherichia coli; Imipenem; Magnetic Resonance Spectroscopy; Meropenem; Penicillin G; Thienamycins | 2011 |
Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence.
Topics: Animals; Bacterial Proteins; Cefepime; Cefoxitin; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genetic Complementation Test; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Sequence Data; Phagocytosis; Porins; Sequence Analysis, DNA; Thienamycins; Virulence | 2011 |
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Cost Savings; Cross Infection; Drug Costs; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Escherichia; Health Policy; Hospitals; Humans; Imipenem; Klebsiella; Meropenem; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Staphylococcus aureus; Teicoplanin; Thienamycins; Turkey; Vancomycin | 2011 |
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Female; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2011 |
Continuous epileptiform discharges in patients treated with cefepime or meropenem.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Belgium; Cefepime; Cephalosporins; Cross-Over Studies; Electroencephalography; Epilepsy; Female; Humans; Male; Meropenem; Middle Aged; Pharmacy Service, Hospital; Retrospective Studies; Thienamycins | 2011 |
Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Utilization; Health Policy; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Policy; Pseudomonas aeruginosa; Switzerland; Thienamycins; Time Factors | 2012 |
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Denmark; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Meropenem; Middle Aged; Mycoses; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2012 |
[Current clinical practice in the treatment of febrile neutropenia (FN)].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Critical Pathways; Evidence-Based Medicine; Fever; Humans; Japan; Meropenem; Neutropenia; Physicians; Practice Guidelines as Topic; Practice Patterns, Physicians'; Surveys and Questionnaires; Thienamycins | 2011 |
Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Clavulanic Acid; Extensively Drug-Resistant Tuberculosis; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Thienamycins | 2012 |
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fever; Humans; Male; Meropenem; Middle Aged; Ofloxacin; Prospective Studies; Prostate; Prostatic Neoplasms; Quinolones; Sepsis; Thienamycins; Treatment Outcome | 2012 |
Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate.
Topics: Amino Acid Sequence; Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; DNA-Binding Proteins; DNA, Bacterial; Histones; Humans; Imipenem; Integrons; Klebsiella oxytoca; Meropenem; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Sequence Alignment; Spain; Thienamycins | 2012 |
[Marked reactive plasmacytosis accompanied by drug eruption in a patient with aplastic anemia].
Topics: Anemia, Aplastic; Cefepime; Cephalosporins; Cyclosporine; Dexamethasone; Diagnosis, Differential; Drug Eruptions; Female; Flow Cytometry; Humans; Meropenem; Middle Aged; Plasma Cells; Thienamycins; Treatment Outcome | 2012 |
Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.
Topics: Amino Acid Substitution; Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Biocatalysis; Cephalosporins; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli; Kinetics; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutagenesis, Site-Directed; Structure-Activity Relationship; Substrate Specificity; Sulbactam; Thienamycins | 2012 |
Infective endocarditis due to Enterobacter cloacae resistant to third- and fourth-generation cephalosporins.
Topics: Aged; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Endocarditis; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Male; Meropenem; Thienamycins; Treatment Outcome | 2015 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cephalosporins; Colistin; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gentamicins; Meropenem; Microbial Sensitivity Tests; Minocycline; Sulbactam; Thienamycins; Tigecycline | 2012 |
Structure-based computational study of the hydrolysis of New Delhi metallo-β-lactmase-1.
Topics: Ampicillin; beta-Lactamases; Catalysis; Cephalosporins; Hydrogen Bonding; Hydrolysis; Meropenem; Molecular Dynamics Simulation; Protein Binding; Protein Structure, Secondary; Substrate Specificity; Thienamycins | 2013 |
Optic nerve involvement from Pseudomonas aeruginosa -associated skull base osteomyelitis.
Topics: Aged; Anti-Bacterial Agents; Blindness; Cefepime; Cephalosporins; Eye Infections, Bacterial; Humans; Magnetic Resonance Imaging; Male; Meropenem; Middle Aged; Optic Nerve Diseases; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Skull Base; Thienamycins; Visual Acuity | 2013 |
Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.
Topics: Acylation; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefoxitin; Cephalosporins; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Meropenem; Mycobacterium tuberculosis; Solvents; Thienamycins | 2013 |
Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamases; Cell Membrane Permeability; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enzyme Activation; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Humans; Hydrolysis; Meropenem; Microbial Sensitivity Tests; Periplasm; Plasmids; Protein Binding; Thienamycins; Young Adult | 2013 |
Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Brain Diseases; Cefepime; Cephalosporins; Female; Hospitals, University; Humans; Infusions, Intravenous; Japan; Male; Meropenem; Neurotoxicity Syndromes; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Insufficiency; Retrospective Studies; Risk; Seizures; Staphylococcal Infections; Staphylococcus aureus; Thienamycins | 2013 |
The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Cohort Studies; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitalization; Humans; Meropenem; Microbial Sensitivity Tests; Middle Aged; Propensity Score; Thienamycins | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.
Topics: Aerosols; Ampicillin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Chemistry, Pharmaceutical; Equipment Design; Meropenem; Nebulizers and Vaporizers; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, General; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Singapore; Thienamycins; Young Adult | 2013 |
[Analysis of the carbapenemase-producing mechanism of Enterobacteriaceae with decreased susceptibility to carbapenems].
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Enterobacteriaceae; Ertapenem; Gene Amplification; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thienamycins | 2013 |
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin; Treatment Failure | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Molecular and epidemiological characterization of IMP-type metallo-β-lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.
Topics: Aged; Aged, 80 and over; Bacteremia; Bacterial Proteins; beta-Lactamases; Cephalosporins; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Hospital Mortality; Humans; Imipenem; Infection Control; Inosine Monophosphate; Japan; Male; Meropenem; Middle Aged; Phylogeny; R Factors; Retrospective Studies; Risk Factors; Tertiary Healthcare; Thienamycins | 2014 |
Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Convulsants; Disease Susceptibility; Drug Administration Schedule; Electroencephalography; Electroshock; Injections, Intravenous; Male; Meropenem; Mice; Mice, Inbred ICR; Pentylenetetrazole; Seizures; Severity of Illness Index; Species Specificity; Thienamycins | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
The impact of an antimicrobial stewardship programme on the use of antimicrobials and the evolution of drug resistance.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Drug Resistance, Microbial; Drug Utilization; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pharmacy Service, Hospital; Practice Patterns, Physicians'; Program Evaluation; Pseudomonas aeruginosa; Spain; Thienamycins | 2015 |
Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004-2011.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; China; Drug Resistance, Bacterial; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2015 |
[Correlation between the biofilm-forming ability, biofilm-related genes and antimicrobial resistance of Acinetobacter baumannii].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Meropenem; Piperacillin; Prospective Studies; Thienamycins | 2014 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
[Distribution and drug resistance of the pathogenic bacteria from sputum specimens of 1 125 children with tracheo bronchial foreign bodies].
Topics: Bacteria; Cefepime; Cephalosporins; Child; Drug Resistance, Bacterial; Foreign Bodies; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Sputum; Thienamycins | 2015 |
Meropenem and chromacef intermediates observed in IMP-25 metallo-β-lactamase-catalyzed hydrolysis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Catalysis; Catalytic Domain; Cephalosporins; Hydrolysis; Kinetics; Meropenem; Thienamycins; Zinc | 2015 |
Allergic Reactions in Hospitalized Patients With a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem.
Topics: Adult; Aged; Aged, 80 and over; Cephalosporins; Drug Hypersensitivity; Female; Humans; Incidence; Inpatients; Male; Meropenem; Middle Aged; New York; Penicillins; Retrospective Studies; Self Report; Thienamycins; Young Adult | 2017 |
Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cefepime; Cephalosporins; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Listeria monocytogenes; Listeriosis; Meropenem; Neoplasm Recurrence, Local; Sepsis; Thienamycins; Thymus Gland; Thymus Neoplasms; Treatment Outcome | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Case-Control Studies; Cephalosporins; Ciprofloxacin; Cross Infection; Female; Hospitals; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Thienamycins | 2017 |
Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the β-Lactamase from Mycobacterium tuberculosis.
Topics: Ampicillin; Antitubercular Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Drug Synergism; Kinetics; Meropenem; Models, Molecular; Mycobacterium tuberculosis; Thienamycins | 2015 |
Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model.
Topics: Animals; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Levofloxacin; Meropenem; Mice; Microbial Sensitivity Tests; Thienamycins; Thigh | 2015 |
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Synergism; Enterobacteriaceae; Escherichia coli Proteins; Gene Expression; Lactams; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Piperacillin; Plasmids; Protein Isoforms; Thienamycins | 2016 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Antibiotic Resistance Patterns of Gram-Negative Psychrotrophic Bacteria from Bulk Tank Milk.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Food Microbiology; Gram-Negative Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Milk; Pseudomonadaceae; Thienamycins | 2016 |
[Combined intravenous and intrathecal vancomycin in treatment of patients with intracranial infections after craniotomy].
Topics: Central Nervous System Infections; Cephalosporins; Craniotomy; Humans; Injections, Intravenous; Injections, Spinal; Meropenem; Retrospective Studies; Thienamycins; Vancomycin | 2016 |
Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Vancomycin | 2017 |
In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.
Topics: Azabicyclo Compounds; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin; Thienamycins | 2016 |
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 2016 |
Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cephalosporins; Drug Therapy, Combination; Female; Humans; Imipenem; Immunosuppressive Agents; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Retrospective Studies; Survival Analysis; Thienamycins; Treatment Outcome | 2016 |
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Taiwan; Thienamycins | 2016 |
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Drug Stability; Meropenem; Siderophores; Thienamycins | 2016 |
Trends in paediatric and adult bloodstream infections at a Ghanaian referral hospital: a retrospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Blood Culture; Cephalosporins; Child; Child, Preschool; Cloxacillin; Drug Resistance, Bacterial; Female; Ghana; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Hospitals, Teaching; Humans; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Thienamycins | 2016 |
[Study on drug sensitivity against Comamonas testosteroni by Kirby-Bauer disk diffusion method].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Comamonas testosteroni; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2016 |
Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; Cephalosporins; Clavulanic Acid; DNA, Intergenic; Gene Expression; Genetic Loci; Humans; Meropenem; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Protein Binding; Thienamycins; Tuberculosis, Multidrug-Resistant | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Humans; Kinetics; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tandem Mass Spectrometry; Thienamycins | 2017 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Gene Transfer, Horizontal; Humans; Imipenem; Klebsiella; Meropenem; Plasmids; Thienamycins; United Kingdom | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2017 |
Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Kidney; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Ertapenem; Gentamicins; Humans; Imipenem; Italy; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Thienamycins; Tigecycline | 2017 |
Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; Cephalosporins; Drug Stability; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Thienamycins | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
Topics: Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Humans; Immunocompromised Host; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
The mechanism of NDM-1-catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin hydrolysis.
Topics: beta-Lactamases; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Escherichia coli; Hydrolysis; Imipenem; Magnetic Resonance Spectroscopy; Meropenem; Models, Molecular; Penicillins; Thienamycins | 2017 |
Whole-Genome Analysis of an Extensively Drug-Resistance Empedobacter falsenii Strain Reveals Distinct Features and the Presence of a Novel Metallo-ß-Lactamase (EBR-2).
Topics: Amino Acid Sequence; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Flavobacteriaceae; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Penicillin G; Thienamycins | 2018 |
[Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015]
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Cross Infection; Drug Resistance; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Retrospective Studies; Thienamycins | 2016 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
AmpC beta-lactamases in Klebsiella pneumoniae: An emerging threat to the paediatric patients.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefoperazone; Cefoxitin; Cephalosporins; Child; Child, Preschool; Ciprofloxacin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals, Pediatric; Humans; Imipenem; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Pakistan; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2018 |
Detection of
Topics: Animals; Anti-Bacterial Agents; Cambodia; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Farms; Meropenem; Microbial Sensitivity Tests; Plasmids; Swine; Transferases (Other Substituted Phosphate Groups) | 2019 |
Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report.
Topics: Aged; Anti-Bacterial Agents; Antibody Specificity; Antifungal Agents; Autoantibodies; Autoimmune Diseases; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Substitution; Drug Therapy, Combination; Factor V; Factor V Deficiency; Fluoroquinolones; Humans; Levofloxacin; Male; Meropenem; Micafungin; Partial Thromboplastin Time; Pneumonia; Prothrombin Time | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Adequacy of empiric gram-negative coverage for septic patients at an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Gram-Negative Bacteria; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Shock, Septic; Virginia; Young Adult | 2019 |
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
Topics: Abdomen; Adult; Aged; Ceftazidime; Cephalosporins; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Respiratory System; Tazobactam; United States; Urinary Tract | 2020 |
Can ceftolozane-tazobactam treat nosocomial pneumonia?
Topics: Cephalosporins; Cross Infection; Double-Blind Method; Humans; Meropenem; Pneumonia; Tazobactam | 2019 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftazidime; Cephalosporins; Cost-Benefit Analysis; Drug Combinations; Hospitalization; Humans; Intraabdominal Infections; Italy; Meropenem; Models, Economic; Tazobactam | 2019 |
Antimicrobial prescription patterns in a tertiary-care pediatric unit in Thailand.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Antimicrobial Stewardship; Cephalosporins; Child; Child, Preschool; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Microbial; Drug Utilization; Hospitalization; Humans; Infant; Infections; Meropenem; Prevalence; Surveys and Questionnaires; Tertiary Care Centers; Thailand | 2020 |
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Neoplasms; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2020 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
A Cephalosporin Prochelator Inhibits New Delhi Metallo-β-lactamase 1 without Removing Zinc.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Escherichia coli; Meropenem; Zinc | 2020 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.
Topics: Achromobacter; Anti-Bacterial Agents; Bacteriophages; Boronic Acids; Cefiderocol; Cephalosporins; Child; Combined Modality Therapy; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Genotype; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Phylogeny; Sisomicin; Young Adult | 2021 |
Association of beta-lactam allergy documentation and antibiotic use in patients with febrile neutropenia.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Cross-Sectional Studies; Drug Hypersensitivity; Febrile Neutropenia; Humans; Meropenem; Penicillins | 2021 |
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Genomic analysis of carbapenem-resistant Pseudomonas aeruginosa ST143 clone showing susceptibility to broad-spectrum cephalosporins.
Topics: Anti-Bacterial Agents; Cephalosporins; Clone Cells; Genomics; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
Topics: Anti-Bacterial Agents; Boronic Acids; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem | 2021 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT.
Topics: Cephalosporins; Humans; Meropenem; Tazobactam | 2022 |
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Porins | 2022 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
T405, a New Penem, Exhibits
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous | 2022 |
[Antibiotic use for prophylaxis and empirical therapy of fracture-related infections in Germany : A survey of 44 hospitals].
Topics: Anti-Bacterial Agents; Cephalosporins; Fracture Fixation, Internal; Fractures, Open; Hospitals; Humans; Meropenem; Penicillins; Surveys and Questionnaires; Vancomycin | 2023 |
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Clinical Characteristics and Drug Resistance Analysis of 90 Cases of Children with Salmonella Enteritis.
Topics: Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Child; Drug Resistance; Enteritis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Retrospective Studies | 2022 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an
Topics: Adenosine Monophosphate; Ampicillin; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Synergism; Enterococcus faecalis; Ertapenem; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |
Evolution of Beta-Lactamases in Urinary Klebsiella pneumoniae Isolates from Croatia; from Extended-Spectrum Beta-Lactamases to Carbapenemases and Colistin Resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Colistin; Croatia; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Ertapenem; Fluoroquinolones; Humans; Klebsiella pneumoniae; Meropenem; Transcriptome; Zinc; Zinc Sulfate | 2023 |